Targeted sensitization of non-del(5q) malignant cells
AssigneeH. Lee Moffitt Cancer Center and Research Institute, Inc.
InventorsAlan List, Sheng Wei
Life of this patent
Estimating the term…
Abstract
Disclosed are molecules for treating non-del(5q) MDS that mimic allelic deficiency in del5q MDS to sensitize the malignant clones of patient without del(5q). The disclosed molecule contains an inhibitor of Cdc25C, an inhibitor of PP2Acα, or a combination thereof, and a toll like receptor-9 (TLR9) targeting ligand. The molecule can also contain lenalidomide, or an analogue or derivative thereof. Also disclosed is a composition comprising the disclosed molecule in a pharmaceutically acceptable carrier. Also disclosed is a method for treating non-del(5q) meylodysplastic syndrome (MDS) in a subject by administering to the subject a therapeutically effective amount of the disclosed pharmaceutical composition.
Claims7
A molecule comprising
- a nucleic acid inhibitor comprising SEQ ID NO:
- 1, a nucleic acid inhibitor comprising SEQ ID NO:
- 2, or a nucleic acid inhibitor comprising a combination of SEQ ID NOS 1 and 2;
- a toll like receptor-9 (TLR9) targeting ligand;
- and
- lenalidomide.
Dependencies are inferred from the claim text.